Cayco A V, Perazella M A, Hayslett J P
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8029, USA.
J Am Soc Nephrol. 1997 Nov;8(11):1788-94. doi: 10.1681/ASN.V8111788.
Over the past decade, intravenous immune globulin therapy (IVIG) has gained widespread use for a variety of clinical disorders. IVIG treatment is associated with a number of complications, including acute renal failure (ARF). Although the cause of IVIG-associated ARF is unknown, it may be related to the stabilizing agent used in the IVIG preparation. The development and resolution of ARF is typically rapid, but is some cases recovery may be delayed and require renal replacement therapy. In such patients, recurrence of ARF may be avoided by selection of a preparation with a different stabilizing agent. Two cases of IVIG-induced ARF are described, and all reported cases are analyzed to assess the probable mechanism of renal injury.
在过去十年中，静脉注射免疫球蛋白疗法（IVIG）已广泛应用于多种临床疾病。IVIG治疗会引发多种并发症，包括急性肾衰竭（ARF）。尽管与IVIG相关的ARF病因不明，但可能与IVIG制剂中使用的稳定剂有关。ARF的发生和缓解通常很快，但在某些情况下恢复可能延迟，需要进行肾脏替代治疗。在此类患者中，通过选择使用不同稳定剂的制剂可避免ARF复发。本文描述了两例IVIG诱发的ARF病例，并对所有报告病例进行分析，以评估肾损伤的可能机制。
